Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

NCT01841021 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual, loss of sponsor support

Conditions

Peripheral T-Cell Lymphoma

Interventions

DRUG: Brentuximab vedotin

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]